Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common StockBusiness Wire • 01/14/21
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common StockBusiness Wire • 01/13/21
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual ConferenceBusiness Wire • 01/08/21
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye DiseaseBusiness Wire • 01/07/21
Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer's Test Results from Run-in Cohort of Phase 3 TRANQUILITY TrialBusiness Wire • 01/06/21
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612Business Wire • 12/22/20
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and PsoriasisBusiness Wire • 12/17/20
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye DiseaseBusiness Wire • 12/08/20
Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor ConferencesBusiness Wire • 11/13/20
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/05/20
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 11/05/20
Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6Business Wire • 11/04/20
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish InitiationBenzinga • 10/31/20
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate UpdateBusiness Wire • 10/29/20
Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual MeetingBusiness Wire • 10/22/20
Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 10/02/20
Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitBusiness Wire • 09/16/20
Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor ConferencesBusiness Wire • 09/10/20
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 PatientsBusiness Wire • 09/09/20
Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 08/12/20